Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.
Aguilar-Bretones M, Westerhuis BM, Raadsen MP, de Bruin E, Chandler FD, Okba NM, Haagmans BL, Langerak T, Endeman H, van den Akker JP, Gommers DA, van Gorp EC, GeurtsvanKessel CH, de Vries RD, Fouchier RA, Rockx BH, Koopmans MP, van Nierop GP.
Aguilar-Bretones M, et al. Among authors: langerak t.
J Clin Invest. 2021 Nov 1;131(21):e150613. doi: 10.1172/JCI150613.
J Clin Invest. 2021.
PMID: 34499051
Free PMC article.